CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

SA Transcripts159.27K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call CRISPR Therapeutics AG (CRSP) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 2:15 PM EDT Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Participants Gil Blum - Needham & Company, LLC, Research Division Presentation Gil BlumNeedham & Company, LLC, Research Division Good afternoon, everyone, and thanks for joining me at the first day of the Needham Healthcare Conference. My name is Gil Blum, and I'm senior analyst here. I specifically cover immuno-oncology, and it is my pleasure to have Sam Kulkarni, the CEO of CRISPR Therapeutics with me today. Question-and-Answer Session Gil BlumNeedham & Company, LLC, Research Division So Sam, maybe you don't need much of an introduction, but maybe a good place to start just 2025 really marked a transition for the company. Maybe just looking forward, how this company think about the pipeline as we move past CASGEVY. And maybe for those who are unaware, maybe a quick overview across therapeutic areas, where you guys are making progress. Samarth KulkarniCEO & Chairman Yes. Thank you for having us, Gil and we're very excited with where we are as a company. The first -- for those who are new to the story, CRISPR was founded about over 10 years ago now, and the first phase of the company was about getting in the -- first this platform to patients, and that's what we did with CASGEVY which is the first approved CRISPR drug in the world that's treating a number of patients with sickle cell and thalassemia today with our partner, Vertex. The second phase was to then use the same platform, both ex vivo and in vivo to advance a number of different programs forward. And that's where we are today, where we have potentially 6 programs that would read out in the next